

processstepssearch

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1612bxx

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'REGISTRY' AT 14:39:37 ON 22 JUN 2008  
FILE 'REGISTRY' ENTERED AT 14:39:37 ON 22 JUN 2008  
COPYRIGHT (C) 2008 American Chemical Society (ACS)  
COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	3.38	1044.62

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-40.00

=> file reg  
COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	3.38	1044.62

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-40.00

FILE 'REGISTRY' ENTERED AT 14:39:44 ON 22 JUN 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 20 JUN 2008 HIGHEST RN 1029712-63-7  
DICTIONARY FILE UPDATES: 20 JUN 2008 HIGHEST RN 1029712-63-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

Updated Search

processstepssearch

=>

Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\andfhg.str

L25        STRUCTURE UPLOADED

=> d 125

L25 HAS NO ANSWERS

L25                STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.46	1045.08
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-40.00

FILE 'HCAPLUS' ENTERED AT 14:40:19 ON 22 JUN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Jun 2008 VOL 148 ISS 26

FILE LAST UPDATED: 20 Jun 2008 (20080620/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 125/prep

SEARCH PROFILE NOT SUPPORTED FOR AUTOMATED SEARCH AND CROSSOVER

The search profile contains L-numbers or saved item names that include chemical substance terms, chemical structures, or structure screen sets. If you are in a single file environment using the CA file (CA, HCA, ZCA, CAPLUS, HCAPLUS, ZCAPLUS), enter HELP FIRST at an arrow prompt (=>) for information about the REGISTRY automated search and

Updated Search

processstepssearch

crossover feature. REGISTRY supports the following search profiles:

Example 1:

```
=> ACT SCRSTR/Q
L3          STR
L4          SCR 2127
L5          QUE L3 NOT L4
```

These searches are supported:

```
S L5/REG
S SCRSTR/Q/REG
S (L3 NOT L4)/REG
```

These searches are not supported:

```
S L5
S SCRSTR/Q
```

Example 2:

```
=> ACT SCRSTR2/Q
L6          STR
L7          SCR 2127
L8          QUE L6
L9          QUE L7
L10         QUE L8 NOT L9
```

This search is supported:

```
S (L6 NOT L7)/REG
```

These searches are not supported:

```
S L10
S L10/REG
S SCRSTR2/Q
S SCRSTR2/Q/REG
S L8 NOT L9
S (L8 NOT L9)/REG
```

=> file reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	2.69	1047.77
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-40.00

FILE 'REGISTRY' ENTERED AT 14:40:26 ON 22 JUN 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 20 JUN 2008 HIGHEST RN 1029712-63-7  
DICTIONARY FILE UPDATES: 20 JUN 2008 HIGHEST RN 1029712-63-7

Updated Search

processstepssearch

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> d his

(FILE 'HOME' ENTERED AT 13:57:46 ON 22 JUN 2008)

FILE 'REGISTRY' ENTERED AT 14:02:26 ON 22 JUN 2008

L1 STRUCTURE UPLOADED

L2 0 S L1

L3 2 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 14:10:02 ON 22 JUN 2008

L4 1 S L3

FILE 'CAOLD' ENTERED AT 14:10:20 ON 22 JUN 2008

L5 0 S L3

FILE 'REGISTRY' ENTERED AT 14:10:26 ON 22 JUN 2008

L6 STRUCTURE UPLOADED

L7 0 S L6

L8 0 S L6 FULL

L9 STRUCTURE UPLOADED

L10 0 S L9

L11 3 S L9 FULL

FILE 'HCAPLUS' ENTERED AT 14:14:01 ON 22 JUN 2008

L12 1 S L11

FILE 'REGISTRY' ENTERED AT 14:14:11 ON 22 JUN 2008

L13 STRUCTURE UPLOADED

L14 5 S L13

L15 85 S L13 FULL

FILE 'HCAPLUS' ENTERED AT 14:16:39 ON 22 JUN 2008

L16 49 S L15

L17 0 S L16 AND RODE, B?/AU

L18 0 S L16 AND ROZMAN, D?/AU

L19 0 S L16 AND TACER, K?/AU

L20 0 S L16 AND KOCJAN, D?/AU

FILE 'CAOLD' ENTERED AT 14:23:43 ON 22 JUN 2008

L21 2 S L15

FILE 'REGISTRY' ENTERED AT 14:24:00 ON 22 JUN 2008

Updated Search

processstepssearch

L22           1 S 66711-31-7/RN  
              SET NOTICE 1 DISPLAY  
              SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 14:24:25 ON 22 JUN 2008  
L23           1 S 110424-58-3/RN  
              SET NOTICE 1 DISPLAY  
              SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 14:24:39 ON 22 JUN 2008  
L24           1 S 110439-26-4/RN  
              SET NOTICE 1 DISPLAY  
              SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 14:39:44 ON 22 JUN 2008  
L25           STRUCTURE UPLOADED

FILE 'HCAPLUS' ENTERED AT 14:40:19 ON 22 JUN 2008

FILE 'REGISTRY' ENTERED AT 14:40:26 ON 22 JUN 2008

=>  
Uploading C:\Documents and Settings\brobinson1\My  
Documents\stnweb\Queries\andfhg.str

L26           STRUCTURE UPLOADED

=> s 126  
SAMPLE SEARCH INITIATED 14:40:49 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED -       726 TO ITERATE

100.0% PROCESSED       726 ITERATIONS                   5 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:   ONLINE   \*\*COMPLETE\*\*  
                          BATCH    \*\*COMPLETE\*\*  
PROJECTED ITERATIONS:       12904 TO   16136  
PROJECTED ANSWERS:           5 TO       234

L27           5 SEA SSS SAM L26

=> s 126 full  
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 177.90 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y  
FULL SEARCH INITIATED 14:40:53 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED -   13884 TO ITERATE

100.0% PROCESSED       13884 ITERATIONS               85 ANSWERS  
SEARCH TIME: 00.00.01

L28           85 SEA SSS FUL L26

=> file hcaplus  
COST IN U.S. DOLLARS                   SINCE FILE       TOTAL  
  ENTRY       SESSION  
FULL ESTIMATED COST                   178.36       1226.13

Updated Search

processstepssearch

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-40.00

FILE 'HCAPLUS' ENTERED AT 14:40:57 ON 22 JUN 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Jun 2008 VOL 148 ISS 26  
FILE LAST UPDATED: 20 Jun 2008 (20080620/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l28/prep
      49 L28
      4591675 PREP/RL
L29      20 L28/PREP
          (L28 (L) PREP/RL)
```

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.69	1228.82

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-40.00

FILE 'REGISTRY' ENTERED AT 14:41:02 ON 22 JUN 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 JUN 2008 HIGHEST RN 1029712-63-7  
DICTIONARY FILE UPDATES: 20 JUN 2008 HIGHEST RN 1029712-63-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

Updated Search

processstepssearch

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>


Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\2wertfgvb.str

L30 STRUCTURE UPLOADED

=> d 130

L30 HAS NO ANSWERS

L30 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 130

SAMPLE SEARCH INITIATED 14:42:44 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 513 TO ITERATE

100.0% PROCESSED 513 ITERATIONS

25 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 8902 TO 11618

PROJECTED ANSWERS: 200 TO 800

L31 25 SEA SSS SAM L30

=> s 130 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 177.90 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y

FULL SEARCH INITIATED 14:42:48 FILE 'REGISTRY'

Updated Search

processstepssearch

FULL SCREEN SEARCH COMPLETED - 10041 TO ITERATE

100.0% PROCESSED 10041 ITERATIONS 513 ANSWERS  
SEARCH TIME: 00.00.01

L32 513 SEA SSS FUL L30

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	179.28	1408.10
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-40.00

FILE 'HCAPLUS' ENTERED AT 14:42:51 ON 22 JUN 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Jun 2008 VOL 148 ISS 26  
FILE LAST UPDATED: 20 Jun 2008 (20080620/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l32/rct

310 L32  
3112224 RCT/RL  
L33 176 L32/RCT  
(L32 (L) RCT/RL)

=> d his

(FILE 'HOME' ENTERED AT 13:57:46 ON 22 JUN 2008)

FILE 'REGISTRY' ENTERED AT 14:02:26 ON 22 JUN 2008

L1 STRUCTURE UPLOADED  
L2 0 S L1  
L3 2 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 14:10:02 ON 22 JUN 2008

Updated Search



# processstepssearch

L4                   1 S L3

FILE 'CAOLD' ENTERED AT 14:10:20 ON 22 JUN 2008

L5                   0 S L3

FILE 'REGISTRY' ENTERED AT 14:10:26 ON 22 JUN 2008

L6                   STRUCTURE UPLOADED

L7                   0 S L6

L8                   0 S L6 FULL

L9                   STRUCTURE UPLOADED

L10                  0 S L9

L11                  3 S L9 FULL

FILE 'HCAPLUS' ENTERED AT 14:14:01 ON 22 JUN 2008

L12                  1 S L11

FILE 'REGISTRY' ENTERED AT 14:14:11 ON 22 JUN 2008

L13                  STRUCTURE UPLOADED

L14                  5 S L13

L15                  85 S L13 FULL

FILE 'HCAPLUS' ENTERED AT 14:16:39 ON 22 JUN 2008

L16                  49 S L15

L17                  0 S L16 AND RODE, B?/AU

L18                  0 S L16 AND ROZMAN, D?/AU

L19                  0 S L16 AND TACER, K?/AU

L20                  0 S L16 AND KOCJAN, D?/AU

FILE 'CAOLD' ENTERED AT 14:23:43 ON 22 JUN 2008

L21                  2 S L15

FILE 'REGISTRY' ENTERED AT 14:24:00 ON 22 JUN 2008

L22                  1 S 66711-31-7/RN

                    SET NOTICE 1 DISPLAY

                    SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 14:24:25 ON 22 JUN 2008

L23                  1 S 110424-58-3/RN

                    SET NOTICE 1 DISPLAY

                    SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 14:24:39 ON 22 JUN 2008

L24                  1 S 110439-26-4/RN

                    SET NOTICE 1 DISPLAY

                    SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 14:39:44 ON 22 JUN 2008

L25                  STRUCTURE UPLOADED

FILE 'HCAPLUS' ENTERED AT 14:40:19 ON 22 JUN 2008

FILE 'REGISTRY' ENTERED AT 14:40:26 ON 22 JUN 2008

L26                  STRUCTURE UPLOADED

L27                  5 S L26

L28                  85 S L26 FULL

Updated Search

processstepssearch

FILE 'HCAPLUS' ENTERED AT 14:40:57 ON 22 JUN 2008  
L29 20 S L28/PREP

FILE 'REGISTRY' ENTERED AT 14:41:02 ON 22 JUN 2008  
L30 STRUCTURE UPLOADED  
L31 25 S L30  
L32 513 S L30 FULL

FILE 'HCAPLUS' ENTERED AT 14:42:51 ON 22 JUN 2008  
L33 176 S L32/RCT

=> s l33 and l29  
L34 6 L33 AND L29

=> s l34 and rode, b?/au  
404 RODE, B?/AU  
L35 0 L34 AND RODE, B?/AU

=> s l34 and rozman, d?/au  
70 ROZMAN, D?/AU  
L36 0 L34 AND ROZMAN, D?/AU

=> s l34 and tacer, k?/au  
6 TACER, K?/AU  
L37 0 L34 AND TACER, K?/AU

=> s l34 and kocjan, d?/au  
73 KOCJAN, D?/AU  
L38 0 L34 AND KOCJAN, D?/AU


=> d l34, ibib abs hitstr, 1-6

L34 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2005:1345046 HCAPLUS  
DOCUMENT NUMBER: 144:69823  
TITLE: Preparation of heteroarylpyrazoles as p38 kinase  
inhibitors  
INVENTOR(S): Naraian, Ashok S.; Clare, Michael; Collins, Paul W.;  
Crich, Joyce Zuowu; Devraj, Rajesh; Flynn, Daniel L.;  
Geng, Lifeng; Graneto, Matthew J.; Hanau, Cathleen E.;  
Hanson, Gunnar J.; Hartmann, Susan J.; Hepperle,  
Michael; Huang, He; Koszyk, Francis J.; Liao, Shuyuan;  
Metz, Suzanne; Partis, Richard A.; Perry, Thao D.;  
Rao, Shashidhar N.; Selness, Shaun Raj; South, Michael  
S.; Stealey, Michael A.; Talley, John Jeffrey;  
Vazquez, Michael L.; Weier, Richard M.; Xu, Xiangdong;  
Khanna, Ish K.; Yu, Yi; Naing, Win; Walker, John;  
Yang, Syaulan  
PATENT ASSIGNEE(S): Pharmacia Corporation, USA  
SOURCE: U.S., 548 pp.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 5  
PATENT INFORMATION:

Updated Search


processstepssearch

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6979686	B1	20051227	US 2001-21780	20011207
AU 2003200580	A1	20030501	AU 2003-200580	20030217
US 7071198	B2	20060704	US 2004-840734	20040505
US 20070078146	A1	20070405		
PRIORITY APPLN. INFO.:			US 1997-47570P	P 19970522
			AU 1998-75883	A3 19980522
			US 1998-196623	A2 19981120
			US 2000-513351	A3 20000224
			US 2001-21780	A3 20011207
OTHER SOURCE(S):			MARPAT 144:69823	
GI				




- AB Title compds. [I; R1 = H, OH, NH<sub>2</sub>, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 = H, halo, mercapto, aryl, heterocyclyl, etc.; R3 = (un)substituted pyridinyl, pyrimidinyl, quinolinyl, etc.; R4 = H, alkyl, (un)substituted Ph, etc.; and pharmaceutically acceptable salts or tautomers thereof] were prepared by solution phase and solid phase parallel array reactions of ketones with hydrazines. Thus, R<sub>3</sub>CH<sub>2</sub>COMe (R<sub>3</sub> = 4-pyridinyl) was condensed with 3,4-F(MeO)C<sub>6</sub>H<sub>3</sub>CHO to give the butenone (80%), which was cyclocondensed with TsNHNH<sub>2</sub> to afford the title compound II (20.7%). The latter inhibited human p38 kinase activity in vitro with IC<sub>50</sub> of 4.6  $\mu$ M and inhibited tumor necrosis factor  $\alpha$  (TNF $\alpha$ ) and interleukin 1 $\beta$  (IL-1 $\beta$ ) release from human peripheral blood mononuclear cells following stimulation with lipopolysaccharide with IC<sub>50</sub> of 0.5  $\mu$ M. Thus, I are useful for the treatment of inflammation, arthritis, asthma, and other disorders mediated by p38 kinase and TNF $\alpha$ . The pharmaceutical compns. comprising the compound I are disclosed.
- IT 216529-28-1P 216529-30-5P  
 RL: CPN (Combinatorial preparation); CRT (Combinatorial reactant);  
 RCT (Reactant); SPN (Synthetic preparation); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate; preparation of heteroarylpyrazole p38 kinase inhibitors by cyclocondensation of hydrazines with ketones)
- RN 216529-28-1 HCAPLUS
- CN Ethanone, 1-[3-phenyl-2-(4-pyridinyl)oxiranyl]- (9CI) (CA INDEX NAME)


processstepssearch



RN 216529-30-5 HCAPLUS  
CN Ethanone, 1-[3-(2-methylphenyl)-2-(4-pyridinyl)oxiranyl]- (9CI) (CA INDEX NAME)




IT 216528-02-8P  
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)  
(p38 kinase inhibitor; preparation of heteroarylpyrazole p38 kinase inhibitors by cyclocondensation of hydrazines with ketones)  
RN 216528-02-8 HCAPLUS  
CN 1H-Pyrazole-1-acetamide, 3-(4-fluorophenyl)-5-methyl-N-(2-phenylethyl)-4-(4-pyridinyl)-N-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)



IT 271577-29-8  
RL: CRT (Combinatorial reactant); RCT (Reactant); CMBI (Combinatorial study); RACT (Reactant or reagent)  
(preparation of heteroarylpyrazole p38 kinase inhibitors by cyclocondensation of hydrazines with ketones)  
RN 271577-29-8 HCAPLUS  
CN 1-Piperidinecarboxylic acid, 4-[2-[3-(4-fluorophenyl)-2-(4-pyridinyl)oxiranyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Updated Search

processstepssearch



REFERENCE COUNT: 87 THERE ARE 87 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:150531 HCAPLUS

DOCUMENT NUMBER: 138:187765

TITLE: Preparation of heteroarylpyrazoles as p38 kinase inhibitors

INVENTOR(S): Anantanarayan, Ashok; Clare, Michael; Collins, Paul W.; Crich, Joyce Zuowu; Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Graneto, Matthew J.; Hanau, Cathleen E.; Hanson, Gunnar J.; Hartmann, Susan J.; Hepperle, Michael; Huang, He; Koszyk, Francis J.; Liao, Shuyuan; Metz, Suzanne; Partis, Richard A.; Perry, Thao D.; Rao, Shashidhar N.; Selness, Shaun Raj; South, Michael S.; Stealey, Michael A.; Talley, John Jeffrey; Vazquez, Michael L.; Weier, Richard M.; Xu, Xiangdong; Khanna, Ish K.; Yu, Yi

PATENT ASSIGNEE(S): G.D. Searle and Co., USA

SOURCE: U.S., 415 pp., Cont.-in-part of U.S. Ser. No. 196,623. CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6525059	B1	20030225	US 2000-513351	20000224
US 6514977	B1	20030204	US 1998-196623	19981120
WO 2000031063	A1	20000602	WO 1999-US26007	19991117
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 2003200580	A1	20030501	AU 2003-200580	20030217
US 7071198	B2	20060704	US 2004-840734	20040505
US 20070078146	A1	20070405		
PRIORITY APPLN. INFO.:			US 1998-196623	A2 19981120
			WO 1999-US26007	A1 19991117

Updated Search

processstepssearch


US 1997-47570P	P 19970522
AU 1998-75883	A3 19980522
US 1998-83670	A2 19980522
US 2000-513351	A3 20000224
US 2001-21780	A3 20011207

OTHER SOURCE(S): MARPAT 138:187765  
GI



AB Title compds. [I; R<sup>1</sup> = H, OH, NH<sub>2</sub>, (cyclo)alk(en)yl, acyl, aryl, etc.; R<sup>2</sup> = (un)substituted piperidinyl; R<sup>3</sup> = (un)substituted pyrimidinyl; R<sup>4</sup> = (un)substituted Ph; and pharmaceutically acceptable salts or tautomers thereof] were prepared by solution phase and solid phase parallel array reactions of ketones with hydrazines. Thus, R<sup>3</sup>CH<sub>2</sub>COMe (R<sup>3</sup> = 4-pyridinyl) was condensed with 3,4-F(MeO)C<sub>6</sub>H<sub>3</sub>CHO to give the butenone (80%), which was cyclocondensed with TsNHNH<sub>2</sub> to afford the title compound II (20.7%). The latter inhibited human p38 kinase activity in vitro with IC<sub>50</sub> of 4.6 μM and inhibited tumor necrosis factor α (TNFα) and interleukin 1β (IL-1β) release from human peripheral blood mononuclear cells following stimulation with lipopolysaccharide with IC<sub>50</sub> of 0.5 μM. Thus, I are useful for the treatment of inflammation, arthritis, asthma, and other disorders mediated by p38 kinase and TNFα.


IT 216529-28-1P 216529-30-5P  
 RL: CPN (Combinatorial preparation); CRT (Combinatorial reactant);  
 RCT (Reactant); SPN (Synthetic preparation); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate; preparation of heteroarylpyrazole p38 kinase inhibitors by cyclocondensation of hydrazines with ketones)  
 RN 216529-28-1 HCAPLUS  
 CN Ethanone, 1-[3-phenyl-2-(4-pyridinyl)oxiranyl]- (9CI) (CA INDEX NAME)




RN 216529-30-5 HCAPLUS  
 CN Ethanone, 1-[3-(2-methylphenyl)-2-(4-pyridinyl)oxiranyl]- (9CI) (CA INDEX NAME)

Updated Search


processstepssearch



IT 216528-02-8P  
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)  
(p38 kinase inhibitor; preparation of heteroarylpyrazole p38 kinase inhibitors by cyclocondensation of hydrazines with ketones)  
RN 216528-02-8 HCAPLUS  
CN 1H-Pyrazole-1-acetamide, 3-(4-fluorophenyl)-5-methyl-N-(2-phenylethyl)-4-(4-pyridinyl)-N-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)



IT 271577-29-8  
RL: CRT (Combinatorial reactant); RCT (Reactant); CMBI (Combinatorial study); RACT (Reactant or reagent)  
(preparation of heteroarylpyrazole p38 kinase inhibitors by cyclocondensation of hydrazines with ketones)  
RN 271577-29-8 HCAPLUS  
CN 1-Piperidinecarboxylic acid, 4-[2-[3-(4-fluorophenyl)-2-(4-pyridinyl)oxiranyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 75 THERE ARE 75 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

Updated Search

processstepssearch

ACCESSION NUMBER: 2003:92403 HCAPLUS  
DOCUMENT NUMBER: 138:137307  
TITLE: Preparation of heteroarylpyrazoles as p38 kinase inhibitors  
INVENTOR(S): Anantanarayan, Ashok; Clare, Michael; Collins, Paul W.; Crich, Joyce Zuowu; Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Graneto, Matthew J.; Hanau, Cathleen E.; Hanson, Gunnar J.; Hartmann, Susan J.; Hepperle, Michael; Huang, He; Koszyk, Francis J.; Liao, Shuyuan; Metz, Suzanne; Partis, Richard A.; Perry, Thao D.; Rao, Shashidhar N.; Selness, Shaun Raj; South, Michael S.; Stealey, Michael A.; Talley, John Jeffrey; Vazquez, Michael L.; Weier, Richard M.; Xu, Xiangdong; Khanna, Ish K.; Yu, Yi  
PATENT ASSIGNEE(S): G.D. Searle and Co., USA  
SOURCE: U.S., 541 pp., Cont.-in-part of U.S. Ser. No. 83,670. CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 5  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6514977	B1	20030204	US 1998-196623	19981120
CA 2351725	A1	20000602	CA 1999-2351725	19991117
WO 2000031063	A1	20000602	WO 1999-US26007	19991117
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1144403	A1	20011017	EP 1999-965756	19991117
EP 1144403	B1	20041006		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
TR 200102001	T2	20011221	TR 2001-2001	19991117
BR 9915420	A	20020122	BR 1999-15420	19991117
HU 2002000130	A2	20020629	HU 2002-130	19991117
EE 200100268	A	20021216	EE 2001-268	19991117
NZ 512344	A	20031128	NZ 1999-512344	19991117
AU 774262	B2	20040624	AU 2000-21454	19991117
AT 278685	T	20041015	AT 1999-965756	19991117
EP 1500657	A1	20050126	EP 2004-23186	19991117
EP 1500657	B1	20070919		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY			
PT 1144403	T	20050131	PT 1999-965756	19991117
ES 2229809	T3	20050416	ES 1999-965756	19991117
AT 373649	T	20071015	AT 2004-23186	19991117
ES 2289411	T3	20080201	ES 2004-23186	19991117
US 6525059	B1	20030225	US 2000-513351	20000224
ZA 2001003882	A	20021014	ZA 2001-3882	20010514




processstepssearch

MX 2001PA05043	A	20010710	MX 2001-PA5043	20010518
NO 2001002456	A	20010719	NO 2001-2456	20010518
BG 105620	A	20020131	BG 2001-105620	20010619
US 6423713	B1	20020723	US 2001-918481	20010731
HK 1040705	A1	20050304	HK 2002-102213	20020322
US 6617324	B1	20030909	US 2002-114297	20020402
AU 2003200580	A1	20030501	AU 2003-200580	20030217
US 20040176433	A1	20040909	US 2003-374781	20030225
US 7153959	B2	20061226		
US 7071198	B2	20060704	US 2004-840734	20040505
US 20070078146	A1	20070405		

PRIORITY APPLN. INFO.:

US 1997-47570P	P	19970522
US 1998-83670	A2	19980522
AU 1998-75883	A3	19980522
US 1998-196623	A	19981120
EP 1999-965756	A3	19991117
WO 1999-US26007	W	19991117
US 2000-513351	A3	20000224
US 2001-918481	A3	20010731
US 2001-21780	A3	20011207
US 2002-114297	A3	20020402

OTHER SOURCE(S): MARPAT 138:137307  
GI



AB Title compds. [I; R1 = H, OH, NH<sub>2</sub>, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 = (un)substituted piperidinyl or piperazinyl; R3 = (un)substituted pyrimidinyl; R4 = (un)substituted Ph; and pharmaceutically acceptable salts or tautomers thereof] were prepared by solution phase and solid phase parallel array reactions of ketones with hydrazines. Thus, R<sub>3</sub>CH<sub>2</sub>COMe (R<sub>3</sub> = 4-pyridinyl) was condensed with 3,4-F(MeO)C<sub>6</sub>H<sub>3</sub>CHO to give the butenone (80%), which was cyclocondensed with TsNHNH<sub>2</sub> to afford the title compound II (20.7%). The latter inhibited human p38 kinase activity in vitro with IC<sub>50</sub> of 4.6 μM and inhibited tumor necrosis factor α (TNFα) and interleukin 1β (IL-1β) release from human peripheral blood mononuclear cells following stimulation with lipopolysaccharide with IC<sub>50</sub> of 0.5 μM. Thus, I are useful for the treatment of inflammation, arthritis, asthma, and other disorders mediated by p38 kinase and TNFα.

IT 216529-28-1P 216529-30-5P  
RL: CPN (Combinatorial preparation); CRT (Combinatorial reactant); RCT (Reactant); SPN (Synthetic preparation); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent)  
(intermediate; preparation of heteroarylpyrazole p38 kinase inhibitors by


Updated Search

processstepssearch

cyclocondensation of hydrazines with ketones)


RN 216529-28-1 HCAPLUS

CN Ethanone, 1-[3-phenyl-2-(4-pyridinyl)oxiranyl]- (9CI) (CA INDEX NAME)



RN 216529-30-5 HCAPLUS

CN Ethanone, 1-[3-(2-methylphenyl)-2-(4-pyridinyl)oxiranyl]- (9CI) (CA INDEX NAME)




IT 216528-02-8P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)  
(p38 kinase inhibitor; preparation of heteroarylpyrazole p38 kinase inhibitors by cyclocondensation of hydrazines with ketones)

RN 216528-02-8 HCAPLUS

CN 1H-Pyrazole-1-acetamide, 3-(4-fluorophenyl)-5-methyl-N-(2-phenylethyl)-4-(4-pyridinyl)-N-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)



IT 271577-29-8


RL: CRT (Combinatorial reactant); RCT (Reactant); CMBI (Combinatorial study); RACT (Reactant or reagent)  
(preparation of heteroarylpyrazole p38 kinase inhibitors by cyclocondensation of hydrazines with ketones)

RN 271577-29-8 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[3-(4-fluorophenyl)-2-(4-pyridinyl)oxiranyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Updated Search

processstepssearch



REFERENCE COUNT: 76 THERE ARE 76 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:368337 HCAPLUS

DOCUMENT NUMBER: 133:4656

TITLE: Preparation of heteroarylpyrazoles as p38 kinase inhibitors

INVENTOR(S): Anantanarayan, Ashok; Clare, Michael; Collins, Paul W.; Crich, Joyce Z.; Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Graneto, Matthew J.; Hanau, Cathleen E.; Hanson, Gunnar J.; Hartmann, Susan J.; Hepperle, Michael; Huang, He; Khanna, Ish K.; Koszyk, Francis J.; Liao, Shuyuan; Metz, Suzanne; Partis, Richard A.; Perry, Thao D.; Rao, Shashidhar N.; Selness, Shaun Raj; South, Michael S.; Stealey, Michael A.; Talley, John Jeffrey; Vazquez, Michael L.; Weier, Richard M.; Xu, Xiangdong; Yu, Yi

PATENT ASSIGNEE(S): G.D. Searle and Co., USA

SOURCE: PCT Int. Appl., 1210 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2000031063	A1	20000602	WO 1999-US26007	19991117
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6514977	B1	20030204	US 1998-196623	19981120
CA 2351725	A1	20000602	CA 1999-2351725	19991117
EP 1144403	A1	20011017	EP 1999-965756	19991117
EP 1144403	B1	20041006		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			

Updated Search

processstepssearch

BR 9915420	A	20020122	BR 1999-15420	19991117
EE 200100268	A	20021216	EE 2001-268	19991117
NZ 512344	A	20031128	NZ 1999-512344	19991117
AU 774262	B2	20040624	AU 2000-21454	19991117
AT 278685	T	20041015	AT 1999-965756	19991117
ES 2229809	T3	20050416	ES 1999-965756	19991117
US 6525059	B1	20030225	US 2000-513351	20000224
MX 2001PA05043	A	20010710	MX 2001-PA5043	20010518
NO 2001002456	A	20010719	NO 2001-2456	20010518
BG 105620	A	20020131	BG 2001-105620	20010619
HK 1040705	A1	20050304	HK 2002-102213	20020322
AU 2003200580	A1	20030501	AU 2003-200580	20030217
PRIORITY APPLN. INFO.:			US 1998-196623	A 19981120
			US 1997-47570P	P 19970522
			AU 1998-75883	A3 19980522
			US 1998-83670	A2 19980522
			WO 1999-US26007	W 19991117
OTHER SOURCE(S):			MARPAT 133:4656	
GI				




AB Title compds. [I; R1 = H, OH, NH<sub>2</sub>, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 = H, halo, alkyl, alkoxy, (un)substituted piperidinyl, etc.; R3 = pyridyl, pyrimidinyl, quinolyl, etc.; R4 = H, alkyl, heterocyclyl, aryl, etc.] were prepared by reaction of ketones with hydrazines. Thus, R<sub>3</sub>CH<sub>2</sub>COMe (R<sub>3</sub> = 4-pyridinyl) was condensed with 3,4-F(MeO)C<sub>6</sub>H<sub>3</sub>CHO and the product cyclocondensed with TsNHNH<sub>2</sub> to give title compound II. Data for biol. activity of I were given.

IT 216528-02-8P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of heteroarylpyrazole p38 kinase inhibitors by cyclocondensation of hydrazines with ketones)

RN 216528-02-8 HCAPLUS

CN 1H-Pyrazole-1-acetamide, 3-(4-fluorophenyl)-5-methyl-N-(2-phenylethyl)-4-(4-pyridinyl)-N-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)

processstepssearch




IT 271577-29-8

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of heteroarylpyrazole p38 kinase inhibitors by  
cyclocondensation of hydrazines with ketones)

RN 271577-29-8 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[3-(4-fluorophenyl)-2-(4-pyridinyl)oxiranyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 216529-28-1P 216529-30-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP

(Preparation); RACT (Reactant or reagent)

(preparation of heteroarylpyrazole p38 kinase inhibitors by  
cyclocondensation of hydrazines with ketones)

RN 216529-28-1 HCAPLUS

CN Ethanone, 1-[3-phenyl-2-(4-pyridinyl)oxiranyl]- (9CI) (CA INDEX NAME)




RN 216529-30-5 HCAPLUS

CN Ethanone, 1-[3-(2-methylphenyl)-2-(4-pyridinyl)oxiranyl]- (9CI) (CA INDEX NAME)

Updated Search

processstepssearch



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:789144 HCAPLUS

DOCUMENT NUMBER: 130:38377

TITLE: Preparation of heteroarylpyrazoles as p38 kinase inhibitors

INVENTOR(S): Anantanarayan, Ashok; Clare, Michael; Collins, Paul W.; Crich, Joyce Zuowu; Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Hanson, Gunnar J.; Koszyk, Francis J.; Liao, Shuyuan; Partis, Richard A.; Rao, Shashidhar N.; Selness, Shaun Raj; South, Michael S.; Stealey, Michael A.; Weier, Richard M.; Xu, Xiangdong

PATENT ASSIGNEE(S): G.D. Searle and Co., USA; et al.

SOURCE: PCT Int. Appl., 828 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 9852940	A1	19981126	WO 1998-US10436	19980522
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2291115	A1	19981126	CA 1998-2291115	19980522
AU 9875883	A	19981211	AU 1998-75883	19980522
AU 754830	B2	20021128		
ZA 9804358	A	19990524	ZA 1998-4358	19980522
EP 1000055	A1	20000517	EP 1998-923642	19980522
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200000235	T2	20000522	TR 2000-235	19980522
EE 9900527	A	20000615	EE 1999-527	19980522
BR 9809147	A	20000801	BR 1998-9147	19980522
HU 2000001880	A2	20010328	HU 2000-1880	19980522
HU 2000001880	A3	20020328		
JP 2002508754	T	20020319	JP 1998-550650	19980522
NZ 501112	A	20021025	NZ 1998-501112	19980522
AP 1246	A	20040207	AP 1999-1715	19980522
W: GM, GH, KE, LS, MW, SD, SZ, UG, ZW				

Updated Search

processstepssearch

IL 132991	A	20051120	IL 1998-132991	19980522
NO 9905695	A	20000121	NO 1999-5695	19991119
MX 9910759	A	20000531	MX 1999-10759	19991122
BG 64313	B1	20040930	BG 1999-103964	19991208
AU 2003200580	A1	20030501	AU 2003-200580	20030217
PRIORITY APPLN. INFO.:			US 1997-47570P	P 19970522
			AU 1998-75883	A3 19980522
			WO 1998-US10436	W 19980522
OTHER SOURCE(S):		MARPAT 130:38377		
GI				




AB Title compds. [I; R1 = H, NH<sub>2</sub>, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 = H, halo, alkyl, alkoxy, etc.; R3 = pyridyl, pyrimidinyl, quinolyl, etc.; R4 = H, alkyl, heterocyclyl, aryl, etc.] were prepared. Thus, R<sub>3</sub>CH<sub>2</sub>COMe (R<sub>3</sub> = 4-pyridinyl) was condensed with 3,4-F(MeO)C<sub>6</sub>H<sub>3</sub>CHO and the product cyclocondensed with TsNHNH<sub>2</sub> to give title compound II. Data for biol. activity of I were given.

IT 216528-02-8P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of heteroarylpyrazoles as p38 kinase inhibitors)

RN 216528-02-8 HCAPLUS

CN 1H-Pyrazole-1-acetamide, 3-(4-fluorophenyl)-5-methyl-N-(2-phenylethyl)-4-(4-pyridinyl)-N-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)




IT 216529-28-1P 216529-30-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of heteroarylpyrazoles as p38 kinase inhibitors)

RN 216529-28-1 HCAPLUS

Updated Search


processstepssearch

CN Ethanone, 1-[3-phenyl-2-(4-pyridinyl)oxiranyl]- (9CI) (CA INDEX NAME)



RN 216529-30-5 HCAPLUS

CN Ethanone, 1-[3-(2-methylphenyl)-2-(4-pyridinyl)oxiranyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1988:473335 HCAPLUS

DOCUMENT NUMBER: 109:73335

ORIGINAL REFERENCE NO.: 109:12281a,12284a

TITLE: Pyridineethanolamine derivatives, procedure for their preparation, and their use in treating obesity, diabetes mellitus, and increased protein degradation

INVENTOR(S): Alig, Leo; Muller, Marcel

PATENT ASSIGNEE(S): Hoffmann-La Roche, F., und Co. A.-G., Switz.

SOURCE: Eur. Pat. Appl., 16 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
EP 254856	A2	19880203	EP 1987-108706	19870616
EP 254856	A3	19890208		
EP 254856	B1	19910904		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 1287061	C	19910730	CA 1987-538235	19870528
US 4800206	A	19890124	US 1987-57150	19870603
FI 8702589	A	19871228	FI 1987-2589	19870610
AT 66916	T	19910915	AT 1987-108706	19870616
ES 2038619	T3	19930801	ES 1987-108706	19870616
ZA 8704449	A	19880224	ZA 1987-4449	19870619
AU 8774557	A	19880107	AU 1987-74557	19870622
AU 594788	B2	19900315		
IL 82945	A	19910610	IL 1987-82945	19870622


Updated Search



processstepssearch

HU 44508	A2	19880328	HU 1987-2860	19870624
HU 198457	B	19891030		
DK 8703295	A	19871228	DK 1987-3295	19870626
DK 166207	B	19930322		
DK 166207	C	19930816		
NO 8702701	A	19871228	NO 1987-2701	19870626
NO 170973	B	19920928		
NO 170973	C	19930106		
JP 63008374	A	19880114	JP 1987-157957	19870626
US 4988714	A	19910129	US 1988-236802	19880826
PRIORITY APPLN. INFO.:			CH 1986-2608	A 19860627
			CH 1987-1186	A 19870327
			US 1987-57150	A3 19870603
			EP 1987-108706	A 19870616

OTHER SOURCE(S): MARPAT 109:73335  
GI



AB Pyridineethanolamines I [ $n = 1, 2$ ;  $X = H, \text{alkyl}, \text{alkoxyalkyl}, \text{CH}_2\text{CH}_2\text{ORa}$ ;  $Z = Q, Q1, 4\text{-RfC}_6\text{H}_4\text{OCH}_2$ ;  $Y = 4\text{-RC}_6\text{H}_4, Q2$ ;  $R_0 = \text{alkyl}, \text{COR}_4, \text{CR}_5\text{:CHCOR}_4$ ;  $R = R_0, R''$ ;  $R' = H, \text{alkyl}, \text{alkanoyl}, (\text{CH}_2)_1\text{-6OH}, (\text{CH}_2)_1\text{-6O}(\text{CH}_2)_1\text{-6R}_6, (\text{CH}_2)_1\text{-6COR}_4$ ;  $R_1, R_a = \text{alkanoyl}, \text{Bz}, (\text{CH}_2)_1\text{-6OH}$ ;  $R_2, R_b = H, \text{Cl}, \text{Br}, \text{CF}_3$ ;  $R_3, R_5 = H, \text{Me}$ ;  $R_4 = \text{OH}, \text{alkoxy}, \text{NR}_7\text{R}_8$ ;  $R_6 = H, \text{Rg}, \text{OH}, \text{COR}_4$ ;  $R_7, R_8 = H, \text{alkyl}$ ;  $R_c, R_e = H, \text{Cl}, \text{F}, \text{Br}, \text{CF}_3$ ;  $R_d = H, \text{NH}_2$ ;  $R_f = H, \text{alkyl}$ ;  $R_c, R_e = H, \text{Cl}, \text{F}, \text{Br}, \text{CF}_3$ ;  $R_d = H, \text{NH}_2$ ;  $R_f = H, \text{AcNH}, \text{H}_2\text{NCOCH}_2, \text{R}_9\text{CH}_2\text{CH}_2\text{OCH}_2\text{CH}_2\text{O}$ ;  $\text{Rg}, \text{R}_9 = \text{Ph (un)substituted with Cl, F, Br}$ ], useful in treating obesity, diabetes mellitus, and conditions with elevated protein degradation and as feed additives for fattened animals, were prepared by 2 methods: a) alkylation of  $\text{X1X2NCHR}_3(\text{CH}_2)_n\text{Y}$  (1 of  $X_1$  and  $X_2 = H$ , the other =  $X$  or  $Q_3$ ) with an agent introducing the group  $Q_c$  or 1 of group  $X$ ; and b) optionally functionally changing a reactive substituent in a group  $Y$  of the reaction product, optionally esterifying an  $\text{OH}$   $\beta$  to the amine  $N$  atom, and optional conversion of I into a salt. Methylenation of 6-chloro-2-pyridinecarboxaldehyde with  $\text{Me}_2\text{S:CH}_2$  gave 2-chloro-6-epoxyethylpyridine which reacted with 4-[(R)-2-aminopropyl]phenol to give  $\alpha, \alpha'$ -[[[(R)-4-hydroxy- $\alpha$ -methylphenethyl]imino]dimethylen e]bis[(RS)-6-chloro-2-pyridinemethanol] (II) and the corresponding monopyrindine compound. Treating II with  $\text{MeSO}_2\text{OCH}_2\text{CH}_2\text{OEt}$  gave the

# processstepssearch

4-(ethoxyethoxy) analog of II. The latter, at 0.1  $\mu\text{M/kg}$  in rats, gave 165% and 122% O consumption in 1-3 h and 1-12 h, resp., compared with the pre-treatment period O consumption. A formulation comprised

(RS)-6-chloro- $\alpha$ -[[[(R)-4-(2-ethoxyethoxy)- $\alpha$ -methylphenethyl]amino]methyl]-2-pyridinemethanol 250, lactose 200, corn starch 300, corn starch paste 50, Ca stearate 5, and Ca phosphate 45 mg.


IT 55967-94-7P 115548-57-7P 115548-61-3P  
115569-90-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, as intermediate for obesity, diabetes mellitus, and elevated protein degradation remedy)


RN 55967-94-7 HCAPLUS

CN Pyridine, 2-(2-oxiranyl)- (CA INDEX NAME)




RN 115548-57-7 HCAPLUS

CN Pyridine, 4-chloro-2-oxiranyl- (9CI) (CA INDEX NAME)




RN 115548-61-3 HCAPLUS

CN Pyridine, 2-chloro-6-oxiranyl- (9CI) (CA INDEX NAME)



RN 115569-90-9 HCAPLUS

CN Pyridine, 2-chloro-4-oxiranyl- (9CI) (CA INDEX NAME)




Updated Search


processstepssearch

IT 115548-08-8P 115548-09-9P 115548-12-4P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP  
(Preparation); RACT (Reactant or reagent)  
(preparation and reaction of, in preparation of obesity, diabetes mellitus,  
and  
elevated protein degradation remedy)  
RN 115548-08-8 HCAPLUS  
CN 2-Pyridinemethanol,  $\alpha, \alpha'$ -[[[2-(4-hydroxyphenyl)ethyl]imino]bis  
(methylene)]bis-, (R\*,R\*)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 115548-09-9 HCAPLUS  
CN 2-Pyridinemethanol,  $\alpha$ -[[[2-(4-hydroxyphenyl)ethyl]amino]methyl]-  
(CA INDEX NAME)



RN 115548-12-4 HCAPLUS  
CN Pyridine, 2-bromo-6-oxiranyl- (9CI) (CA INDEX NAME)




IT 115548-25-9P 115548-26-0P 115548-27-1P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as remedy for obesity, diabetes mellitus, and elevated  
protein degradation)  
RN 115548-25-9 HCAPLUS  
CN 2-Pyridinemethanol,  $\alpha$ -[[[2-[4-(2-ethoxyethoxy)phenyl]ethyl]amino]met

Updated Search


processstepssearch

hyl]- (CA INDEX NAME)



RN 115548-26-0 HCAPLUS


CN 2-Pyridinemethanol,  $\alpha$ -[[[2-[4-(2-ethoxyethoxy)phenyl]ethyl](2-ethoxyethyl)amino]methyl]- (CA INDEX NAME)



RN 115548-27-1 HCAPLUS

CN 2-Pyridinemethanol,  $\alpha, \alpha'$ -[[[2-[4-(2-ethoxyethoxy)phenyl]ethyl]imino]bis(methylene)]bis-, (R\*, R\*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 34064-35-2 60699-67-4 115548-61-3

RL: RCT (Reactant); RACT (Reactant or reagent)


(reaction of, in preparation of obesity, diabetes mellitus, and elevated protein degradation remedy)

RN 34064-35-2 HCAPLUS


CN Pyridine, 4-(2-oxiranyl)- (CA INDEX NAME)

Updated Search


processstepssearch



RN 60699-67-4 HCAPLUS  
CN Pyridine, 3-oxiranyl- (9CI) (CA INDEX NAME)



RN 115548-61-3 HCAPLUS  
CN Pyridine, 2-chloro-6-oxiranyl- (9CI) (CA INDEX NAME)



=>

Updated Search